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ABSTRACT
Introduction. Following two coronaviral epidemics in 2002 and 2012, December 2019 saw the emergence of a potentially fatal 
coronavirus — SARS-CoV-2, which originated in Wuhan, China. While most coronaviruses are responsible for mild respiratory infec-
tions, they have been demonstrated to be neuroinvasive and neurotropic for over three decades. In this review, we assess whether 
SARS-CoV-2 follows this trend and if the neuroinvasive potential of this novel coronavirus is worthy of further investigation.
Methods. To obtain sources for this study, we performed an online search through Pubmed, Researchgate and Google Scholar, 
finding 537 articles. After analysing them according to PRISMA, we included 14 in this review.
Discussion. Data regarding neurological manifestations of SARS-CoV-2 is scarce and mostly inconsistent. There are however 
identifiable trends which might provide a basis for future research. There is strong evidence that this novel coronavirus may be 
neuroinvasive and could cause a wide array of neurological symptoms and complications. Cerebrospinal fluid testing may shed 
more light on the occurrence of SARS-CoV-2 in the central nervous system. Clarification of the respiratory failure mechanisms 
requires post mortem examinations and brain tissue analysis, and further research is of the utmost importance. However, we 
strongly believe that the existing evidence is enough to raise awareness among clinicians and help guide them through the 
diagnosis and optimal therapy of COVID-19 patients.
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Introduction
The first reports of human coronaviruses (HCoV) came in 
the 1960s from patients with the common cold [1]. Since then, six 
human pathogenic coronaviruses have been identified [2]. Most 
of them are responsible for mild respiratory infections. However, 
more recently we have experienced two major HCoV epidemics 
– severe acute respiratory syndrome (SARS) in 2002 and Middle 
East respiratory syndrome (MERS) in 2012. December 2019 saw the 
emergence of another potentially fatal coronavirus — SARS-CoV-2, 
which originated in Wuhan, China [3]. In contrast to the previous 
epidemics, the novel coronavirus quickly spread worldwide. By 
12 June, 2020 it had caused 7,410,510 confirmed infections and 
418,294 deaths [4] and had become of paramount global concern.
Coronaviruses have been demonstrated to be neuroinva-
sive and neurotropic for over three decades [5]. In this review 
we assess whether SARS-CoV-2 follows this trend and if the 
neuroinvasive potential of this novel coronavirus is worthy of 
further investigation.
Over the last few months, there have been numerous 
reports and reviews on this topic, although they have varied 
immensely in terms of their data presentation and conclusions. 
This review is an attempt to gather the available facts, suggest 
provisional conclusions, and encourage further research. We 
believe that such research is crucial in order to come closer 
to understanding the virus in that it makes the data more 
accessible and better organised.
Methods and results
To obtain sources for this study, we performed an online 
search through Pubmed, Researchgate and Google Scholar, 
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Figure 1. Flowchart of selection process according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
in which we used the key words “coronavirus” and “COVID” 
together with the words “neurological”, “neurology”, “nervous” 
and “CNS”. We found 537 articles, which we then analysed 
according to PRISMA rules [6] (Fig. 1). This left us with 
14 studies which we divided into two groups, set out below 
in Tables 1 and 2. 
In Table 1 we set out those which focused specifically on 
neurological manifestations of COVID-19. Table 2 on the 
other hand includes more general research, i.e. studies which 
were not primarily focused on neurological disorders, however 
mentioned non-specific neurological symptoms or disorders.
The authors of both Chinese observational studies [7, 8] 
reported a high incidence of cerebrovascular diseases, in-
cluding ischaemic stroke, among COVID-19 patients. Mao 
et. al. also stated that symptoms from the nervous system 
were significantly more common in severe cases than in non-
-severe. In addition, Helms et. al. [9] reported neurological 
signs in 84% of the patients who had been admitted to hospital 
because of acute respiratory distress syndrome (ARDS) due 
to COVID-19.
Single cases have also been reported suggestive of diverse 
symptoms [10–15]. Cerebrospinal fluid (CSF) testing has 
provided various results. In the first case, the CSF tested 
negative for SARS-CoV-2. In the second one, specific RNA 
was not detected in the nasopharyngeal swab, but was present 
in the CSF. The patient, who developed Acute Haemorrhagic 
Necrotising Encephalopathy visible in CT and MRI, was po-
sitive for SARS-CoV-2, but due to trauma a CSF test could 
not be performed. 
The next two studies set out in Table 1 describe six cases of 
Guillain–Barré Syndrome (GBS) associated with coronaviral 
infection. All five patients from the first study tested positive 
for the novel coronavirus at the onset of neurological symp-
toms, while the last one had a positive test on day eight. Ho-
wever, CSF was either not tested or tested negative for SARS-
-CoV-2 RNA. The onset of the neurological symptoms also 
varied. For patients from the first study, onset was 5–10 days 
after COVID-19 manifestation, while for the patient from the 
latter study, it was eight days before. The last included study 
highlighted the possibility of Miller Fisher Syndrome and 
polyneuritis cranialis occurrence (arguably due to an aberrant 
immune response to the coronaviral infection) during the 
COVID-19 pandemic.
A more thorough CSF comparison was not possible, as the 
studies either did not include detailed CSF profiles or provided 
only selective data. 
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Table 1. Studies on neurological complications of COVID-19




Neurological manifestations of hospitalised patients with Coro-
navirus disease 2019 in Wuhan, China [7]
214 78 (36.4%) Acute cerebrovascular diseases, impaired conscio-
usness and skeletal muscle injury
Acute cerebrovascular disease following COVID-19: a single-
-centre,
retrospective, observational study [8]
221 11 (5%) Acute ischaemic stroke
1 (0.5%) Cerebral haemorrhage
1 (0.5%) Cerebral venous sinus thrombosis (CVST)
Neurological features in severe SARS-CoV-2 infection [9] 58 40 (69%) Agitation
39 (67%) Corticospinal tract signs
14 (36%) Dysexecutive syndrome
Concomitant neurological symptoms observed in a patient 
diagnosed with Coronavirus disease 2019 [10]
1 1 (100%) Altered consciousness and psychiatric symptoms, 
with positive signs based on neurological exami-
nation (CSF -)
A first case of meningitis/encephalitis associated with SARS-
-Coronavirus-2 [11]
1 1 (100%) Headache, fatigue, generalised seizures, meningitis 
(CSF +)
COVID-19–associated acute haemorrhagic necrotising encepha-
lopathy: CT and MRI features [12]
1 1 (100%) Acute haemorrhagic necrotising encephalopathy
Guillain–Barré syndrome associated with SARS-CoV-2 [13] 5 5 (100%) Guillain–Barré syndrome (CSF -)
Guillain-Barré syndrome associated with SARS-CoV-2 infection: 
causality or coincidence? [14]
1 1 (100%) Guillain–Barré syndrome
Miller Fisher syndrome and polyneuritis cranialis in COVID-19 
[15]
2 1 (50%) Miller Fisher syndrome (CSF -)
1 (50%) Polyneuritis cranialis (CSF -)
Table 2. Nonspecific neurological manifestations in general studies




Clinical features of patients infected with 2019 novel coronavi-
rus in Wuhan, China [16]
41 18 (44%)
3 of 38 (8%)
Myalgia, fatigue, headache
Clinical course and outcomes of critically ill patients with SARS-
-CoV-2 pneumonia in Wuhan, China: a single-centre, retrospec-





Clinical characteristics of 138 hospitalised patients with 2019 





Epidemiological and clinical characteristics of 99 cases of 2019 






Clinical features of 85 fatal cases of COVID-19 from Wuhan: 
a retrospective observational study [20]
85 No data Myalgia, headache
There have been more studies on the general characteristics 
and symptoms of novel coronavirus patients [16–20] (Tab. 2). 
In all of them, headache and myalgia were reported. However, 
these symptoms are not specific to the nervous system and the-
refore it is difficult to tie them to the possible SARS-CoV-2 CNS 
invasion. With the disease still being relatively little understood, 
the reports are valuable yet remain inconsistent.
Discussion
It has been reported that neurological compromise is 
a part of the SARS-CoV-2 infection and might occur in up to 
one in three COVID-19 patients [21]. The presented studies 
do not provide definitive conclusions however, because the 
occurrence of the neurological diseases might be a coincidence 
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rather than a correlation. Although the data is unconvincing, 
there are reasons to investigate the impact of SARS-CoV-2 on 
the nervous system. While the novel coronavirus is a newly 
discovered pathogen, we have additional knowledge about 
other coronaviruses. They have natural neuroinvasive traits 
[22], although they are not very well characterised. Coronaviral 
RNA can be found in human brain samples [23]. It has been 
established that these viruses can create a persistent infection 
in human cells representative of the CNS [24].
As with all viral agents, there are two possible routes 
for the coronaviruses to enter the CNS: haematogenous or 
neuronal retrograde. It seems that HCoV may be able to use 
both ways. Infected leukocytes could provide a vector to use 
the haematogenous route [25], while a recent study on HCoV 
OC43 identifies the clear way of its neuroinvasiveness in the 
olfactory nerve [26]. Thus we can expect the novel coronavirus 
to have neuroinvasive potential. This is further reinforced by 
proofs we have from previous coronavirus epidemics – namely 
SARS and MERS. These viruses have been reported to not only 
appear in CSF [27] but to also cause neurological symptoms. 
[28–29]. Coronaviral infections have caused several acute 
neurological complications, including among others viral me-
ningitis, anosmia, encephalitis, and myositis [30]. It would be 
logical to expect SARS-CoV-2 to be possibly neuroinvasive as 
well, as it in many ways resembles its predecessor SARS-CoV 
both genetically and clinically [31].
The knowledge we have today allows us to go further than 
a mere educated guess. A study by Baig et al. ties in the expres-
sion of ACE2 and neurovirulence of SARS-CoV-2 [32]. They 
reported that the virus disseminated in circulation may intera-
ct with its spike protein with the ACE2 receptors in the cerebral 
capillaries. Further interaction with neuronal ACE2 receptors 
could cause significant damage without much inflammation. 
This was previously also true for SARS-CoV [33] and might 
explain how the virus may use the aforementioned haemato-
genous entry route to the CNS. The growing number of reports 
indicating that SARS-CoV-2 may be responsible for anosmia 
and dysgeusia [34–35] suggests that the suspected olfactory 
route could also be confirmed.
This theory is becoming backed up by examples. We alre-
ady have the first reports of a patient who tested positive for 
SARS-CoV-2 in CSF by gene sequencing [36]. Another patient, 
from the second case report in Table 1, had meningitis/encep-
halitis symptoms and had specific viral RNA discovered in his 
CSF, even though the test by nasopharyngeal swab turned out 
negative. Wu et al. have named viral encephalitis, infectious 
toxic encephalopathy, and acute cerebrovascular disease as 
the main nervous system diseases related to coronaviral in-
fections [37] — the same complications as were reported in 
the studies set out in Table 1. Wichmann et al. from Dr Klaus 
Püschel’s laboratory conducted post mortem examinations of 
PCR-confirmed COVID-19 patients. Deep venous thrombosis 
was revealed in seven out of 12 patients, while pulmonary 
embolism was a direct cause of death for four of them, thereby 
underlining the importance of COVID-induced coagulopathy 
[38]. The commonly described cerebrovascular incidents could 
be also caused by elevated (due to coronaviral infection) levels 
of anticardiolipin antibodies, as suggested by Zhang et al. [39]. 
Although single studies encapsulated in Tables 1 and 2 do 
not provide conclusive data, nonetheless in the light of other 
described findings we should be extremely careful and aware 
of the likely neuroinvasiveness of SARS-CoV-2.
There is another important aspect of the SARS-CoV-2 neu-
rovirulence worth mentioning. The main cause of death for 
COVID-19 is respiratory failure [40].  Li, Bai and Hashi-
kawa highlighted the possibility that it could be the SARS-
-CoV-2 CNS invasion which partially causes acute respiratory 
failure [41]. Previous coronaviruses (SARS-CoV, MERS-CoV) 
have been proven to heavily infect the thalamus and brainstem. 
According to Li et al., the cause of death could be suppression 
of the brainstem respiratory centre. This could explain why 
some patients are more vulnerable to death by respiratory 
failure. Additionally, myopathy and rhabdomyolysis were 
reported to occur in SARS patients [42, 43]. 
There is a possibility that not only could the respiratory 
centre in the CNS be damaged by SARS-CoV-2, but that also 
the muscle injuries may play a part in the process of respira-
tory failure [44].
All of the presented findings build towards a cohesive 
hypothesis. There is strong evidence supporting the theory 
that SARS-CoV-2 is naturally neuroinvasive and could cause 
a wide array of neurological symptoms and complications. 
CSF testing may shed more light on the occurrence of SARS-
-CoV-2 in the CNS. Clarification of the respiratory failure 
mechanisms requires post mortems and brain tissue analysis. 
Further research is of the utmost importance. However, we 
strongly believe that there is enough existing evidence to raise 
awareness among clinicians and help guide them through the 
diagnosis and optimal therapy of COVID-19 patients.
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